Equipoise - Boldabolic (boldenone undecylenate)
Equipoise (Boldenone Undecylenate Injection) is a long-acting injectable anabolic agent, supplied in a vial providing 50 mg boldenone undecylenate per mL in sesame oil with 3% (w/v) benzyl alcohol as a preservative.
Equipoise is a steroid ester possessing marked anabolic properties and a minimal amount of androgenic activity.
Anabolic and androgenic agents have come to be used widely in the treatment of certain pathophysiological or catabolic processes in man and animals. In many instances it is desirable to maintain a constant level of effect over a long period of time. Equipoise is a long-acting injectable agent which has a rapid onset of action; this is advantageous and is preferred over frequent oral dosing or even repeated injections.
Anabolic agents are related to the sex hormones, but each varies in its anabolic and androgenic effect. Compounds such as methyltestosterone have anabolic activity, but with prolonged use, animals develop marked androgenic activity which makes these compounds unsuitable for prolonged therapy.
Pharmacological studies conducted in laboratory animals to evaluate the pharmacological activity characterized Equipoise as having distinct anabolic properties together with a certain degree of androgenic activity. It does not have marked antigonadotropic properties nor does it produce any clear-cut effects on the endometrium, conditions that are commonly observed when similar substances are used.
In clinical trials, at the recommended dosage, Equipoise had a marked anabolic effect in debilitated horses; appetite improved, vigor increased and improvement was noted in musculature and haircoat. This would be expected with an anabolic agent such as Equipoise, particularly where there had been marked tissue breakdown associated with disease, prolonged anorexia or overwork.
Equipoise (Boldenone Undecylenate Injection) is recommended as an aid for treating debilitated horses when an improvement in weight, haircoat or general physical condition is desired. Debilitation often follows disease or may occur following overwork and overexertion.
Equipoise improves the general state of debilitated horses, thus aiding in correcting weight losses and improving appetite. It is not a substitute for a well-balanced diet. Optimal results can be expected only when good management and feeding practices are utilized.
Equipoise should be considered only as adjunctive therapy to other specific and supportive therapy for diseases, surgical cases and traumatic injuries.
For intramuscular use.
With Equipoise (Boldenone Undecylenate Injection), androgenic (over aggressiveness) effects may be noted. If these effects occur, they may persist for up to 6 to 8 weeks. No additional injections of boldenone undecylenate should be administered.
Store at room temperature; avoid freezing.
The side effects associated with Equipoise are generally mild. The structure of boldenone allows it to convert into estrogen, but it does not have an extremely high affinity to do so. It is usually only heaved of with very sensitive individuals or (again) those venturing high in dosage.
Equipoise can also produce distinct androgenic side effects. Incidences of oily skin, acne, increased aggression and hair loss are likewise all possible with this compound, although will typically be related to the use of higher doses.